InSitu Biologics, Inc.
About InSitu Biologics, Inc.
InSitu Biologics, Inc. is a biotechnology company that develops a multi-phase prolonged-release drug delivery platform for the localized treatment of pain, cancer, and infection. It is a near-clinical-stage Life Sciences company developing injectable sustained-release drug delivery technologies to extend therapeutic exposure to the target site. The company’s lead product candidate, INSB200™, is a ropivacaine-based sustained-release peripheral nerve block agent for post-operative pain management. Preclinical animal data have demonstrated sustained therapeutic release for up to five days while remaining within targeted safety parameters.
- 🔗 InSitu Biologics, Inc. Valuation & Funding History
- 🔗 InSitu Biologics - 2026 Company Profile, Team, Funding & Competitors - Tracxn
- 🔗 InSitu Biologics, Inc. Company Overview, Contact Details & Competitors | LeadIQ
- 🔗 InSitu Biologics Stock Price, Funding, Valuation, Revenue & Financial Statements
- 🔗 InSitu Biologics, Inc.
Key highlights
- Raised $15,037,850 via private placement in biotechnology sector.
- Developing INSB200 for sustained post-operative pain relief up to five days.
- Backed by investors including In5 and Manhattan Street Fund across multiple rounds.
- Near-clinical stage with focus on localized treatment of pain, cancer, and infection.
- Headquartered in Oakdale, MN with total funding estimates ranging $12M-$15.17M.
Ask StreetZero about InSitu Biologics, Inc.
Put our AI to work on this deal.
Similar companies
Other Biotechnology deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account